Philogen S.p.A. (BIT: PHIL)

Market Cap	769.53M
Revenue (ttm)	3.92M
Net Income (ttm)	-29.35M
Shares Out	40.29M
EPS (ttm)	-0.73
PE Ratio	n/a
Forward PE	17.44
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,668
Open	19.50
Previous Close	19.10
Day's Range	18.65 - 19.50
52-Week Range	16.30 - 21.90
Beta	0.19
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 7, 2024

About Philogen

Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases. It is developing Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF developed intralesional treatment for locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and Darleukin (L19IL2), a human immunostimulatory product consisting of the human L19 antibody fused to the human cytokine interleukin-2 ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 165
• Stock Exchange: Borsa Italiana
• Ticker Symbol: PHIL

Financial Performance

In 2023, Philogen's revenue was 24.73 million, a decrease of -8.20% compared to the previous year's 26.94 million. Losses were -6.16 million, 14.6% more than in 2022.